Abbott LaboratoriesMEX:ABT +1.26%81 EBITDA Margin % is 21.73% as of Mar. 2026, which is 15% below its 10-year median of 25.64. GuruFocus rates MEX:ABT with a GF Score™ of 81/100 and a GF Value™ of MXN2,267.11 (Modestly Undervalued). Among 816 Medical Devices & Instruments companies, Abbott Laboratories ranks better than 86.15% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abbott Laboratories's EBITDA for the
three
months ended in Mar. 2026 was MXN43,747 Mil. Abbott Laboratories's Revenue for the
three
months ended in Mar. 2026 was MXN201,317 Mil. Therefore, Abbott Laboratories's EBITDA margin for the quarter that ended in Mar. 2026 was 21.73%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abbott Laboratories EBITDA Margin % Related Terms
Abbott Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ABT vs SYK, MDT, BSX: EBITDA Margin % Comparison
For the Medical Devices subindustry, Abbott Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (MEX:ABT) has a EBITDA Margin % of 21.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott Laboratories and its competitors. This is 15% below median its historical median of 25.64. Over the past decade, Abbott Laboratories' EBITDA Margin % has ranged from 15.33 to 28.51. According to the industry distribution chart, Abbott Laboratories ranks #113 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Abbott Laboratories' EBITDA Margin % too high?
Abbott Laboratories' current EBITDA Margin % of 21.73% is 15% below median its 10-year median of 25.64. Over the past 10 years, this metric has ranged from a low of 15.33 to a high of 28.51. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Abbott Laboratories' value of 21.73% is 190.7% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #113 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Abbott Laboratories has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' EBITDA Margin % compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #113 out of 816 companies for EBITDA Margin %. This places Abbott Laboratories in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Abbott Laboratories' value of 21.73% is 190.7% above this benchmark. Historically, Abbott Laboratories' own EBITDA Margin % has ranged from 15.33 to 28.51 over the past decade. While the company's 10-year median is 25.64 vs. the industry median of 7.48, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current EBITDA Margin % of 21.73% is 190.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current EBITDA Margin % is 21.73%, which is 15% below median its own 10-year median of 25.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN2,267.11, compared to a current price of MXN1,605.00 — trading 29.2% below its estimated fair value. The current EBITDA Margin % is 21.73%, which is 15% below median its 10-year median of 25.64 and 190.7% above the Medical Devices & Instruments industry median of 7.48. Abbott Laboratories' overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current EBITDA Margin % is 21.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of MXN1,605.00 is trading 29.2% below its estimated GF Value™ of MXN2,267.11.
GuruFocus considers Abbott Laboratories to be Modestly Undervalued.
Key valuation signals for MEX:ABT:
EBITDA Margin %: 21.73% (15% below median its 10-year median of 25.64)
GF Value™: MXN2,267.11 vs. price of MXN1,605.00 (29.2% below fair value)
Industry Position: 190.7% above the Medical Devices & Instruments median (#113 of 816)
No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
81GF Score
Get the complete analysis for MEX:ABT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABT has been successfully added to your 
